affirmed its prior guidance for 2009. On a comparable and currency-neutral basis, the Atlanta-based company said consolidated financial results for 2009 will reflect low single-digit operating income growth and mid single-digit EPS growth.
Including the expected impact of currency translations, the company also expects free cash flow of approximately $600 million, and capital expenditures of approximately $900 million. Free cash flow will continue to be used primarily for debt reduction. At current rates, foreign currency translations would have a negative impact on expected 2009 comparable EPS of approximately 20 cents.
, a Cambridge, Mass., biotech company, said fourth-quarter revenue rose 13% to $1.17 billion, reflecting an approximate $39 million negative impact of foreign exchange, from $1.04 billion in the same period in 2007.
Total revenue in 2009 is expected to reach $5.2 billion to $5.4 billion. The company's guidance reflects an approximate $150 million unfavorable impact of foreign exchange.
This article was written by a staff member of TheStreet.com.